March 21, 2012
/PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of three new Onco
DX® studies including data demonstrating the test's cost-effectiveness within the German and Hungarian healthcare systems, and Israeli data showing the test's impact on treatment decisions in early-stage invasive breast cancer patients with lymph-node positive status. These findings will be presented during poster sessions at the 8th European Breast Cancer Conference (EBCC) in
"We now have eight clinical studies involving more than 5,000 patients across
, showing the value the Onco
DX test brings to patients, physicians and payors," said
, director, medical affairs in
, Genomic Health. "As international use of the Onco
DX breast cancer test increases, it's important to not only have strong clinical data but also to demonstrate that using the test is cost effective in different healthcare systems."
DX breast cancer test has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Multiple studies conducted in
the United States
have shown the use of the test to change treatment decisions in approximately 30 percent of patients. Additionally, nine health economic analyses have consistently demonstrated the cost effectiveness of Onco
DX in the assessed healthcare systems in
and North America.
Health Economics Analyses in Germany and Hungary
's Cost Effectiveness
"As physicians, we are challenged to provide quality patient care while exercising economic sense. Onco
DX is a unique tool we can use to help guide treatment recommendations for early-stage breast cancer patients in a cost effective manner," said
, M.D., professor of gynecology, Interdisciplinary Oncology Center,
, Germany. "Onco
DX is already included in international clinical guidelines such as ESMO, St. Gallen, ASCO and NCCN(1) and our research demonstrates that Onco
DX is cost effective and impacts treatment decisions ensuring that the right patients benefit from chemotherapy, while others are spared unnecessary treatment and associated toxicities."
Using Oncotype DX in Lymph Node-Positive Patients in Israel is Likely to Reduce Use of Chemotherapy
- The results of a large prospective German multicenter study involving 366 patients have shown that use of the Onco type DX changed initial recommendations in 33 percent of cases and demonstrate that using the test would be associated with an increased survival and be cost effective in Germany. "Using the 21-gene breast cancer assay in adjuvant decision-making in ER-positive (ER+) early breast cancer (EBC) is cost-effective: Results of a large prospective German multicenter study" (Abstract #302) will be presented on Friday, March 23.
- Additionally, a health economics analysis from Hungary finds the Onco type DX compares favorably with other oncology related health technologies being utilized in the country and that using the Onco type DX assay is likely to be cost effective in Hungary. "The impact of chemotherapeutic regimens on the cost-utility analysis of Onco type DX assay" (Abstract #347) will be presented on Thursday, March 22.
About Genomic Health
- In an evaluation of the relationship between the Recurrence Score® results and treatment decisions in patients with estrogen receptor-positive, node-positive, breast cancer in Israel, researchers found that patients who had the Onco type DX test were less likely to be recommended chemotherapy compared to patients who did not have the test even when adjusting for variables such as grade and nodal status (p<0.001). The study included 282 patients who received the Recurrence Score and 669 control patients who did not receive the test. "Recurrence Score (RS) and treatment decisions in node-positive (N+), estrogen receptor-positive (ER+) breast cancer patients in Israel" (Abstract #433) will be presented on Friday, March 23.
, Inc. (NASDAQ: GHDX) is a global cancer company focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its lead product, the Onco
DX® breast cancer test, has been shown to predict the likelihood of
as well as recurrence in invasive
and has been shown to the predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Onco
DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. As of
December 31, 2011
, more than 10,000 physicians in over 65 countries had ordered more than 265,000 Onco
DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. In February, the company announced plans to form a new wholly owned genetics subsidiary to focus on the commercial applications of the human genome, with the goal of making commercial services available to physicians and patients in 2013. The company is based in
Redwood City, California
with European headquarters in
. For more information, please visit,
. To learn more about Onco
DX tests, visit: